AU6959898A - Compounds and therapies for the prevention of vascular and non-vascular pathol ogies - Google Patents
Compounds and therapies for the prevention of vascular and non-vascular pathol ogiesInfo
- Publication number
- AU6959898A AU6959898A AU69598/98A AU6959898A AU6959898A AU 6959898 A AU6959898 A AU 6959898A AU 69598/98 A AU69598/98 A AU 69598/98A AU 6959898 A AU6959898 A AU 6959898A AU 6959898 A AU6959898 A AU 6959898A
- Authority
- AU
- Australia
- Prior art keywords
- vascular
- ogies
- pathol
- therapies
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4385297P | 1997-04-11 | 1997-04-11 | |
US60043852 | 1997-04-11 | ||
PCT/US1998/007063 WO1998046588A2 (en) | 1997-04-11 | 1998-04-09 | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6959898A true AU6959898A (en) | 1998-11-11 |
Family
ID=21929208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU69598/98A Abandoned AU6959898A (en) | 1997-04-11 | 1998-04-09 | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
Country Status (3)
Country | Link |
---|---|
US (5) | US6117911A (US06734208-20040511-C00003.png) |
AU (1) | AU6959898A (US06734208-20040511-C00003.png) |
WO (1) | WO1998046588A2 (US06734208-20040511-C00003.png) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1510220B1 (en) * | 1993-05-13 | 2008-07-23 | Poniard Pharmaceuticals, Inc. | Therapeutic inhibitor of vascular smooth muscle cells |
US6197789B1 (en) * | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
ATE406909T1 (de) * | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
JP2000515523A (ja) * | 1996-07-22 | 2000-11-21 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 |
EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
AR023819A1 (es) * | 1999-05-03 | 2002-09-04 | Astrazeneca Ab | FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION |
US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
DK1214077T3 (da) * | 1999-09-21 | 2004-06-07 | Inst Cardiologie Montreal | Lokal indgivelse af 17-beta östradiol til forbedring af karendotelfunktionen efter karskade |
CN1951899B (zh) * | 2000-02-16 | 2012-02-01 | 布里格姆及妇女医院股份有限公司 | 阿司匹林触发的脂质介体 |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
WO2002015882A1 (en) * | 2000-08-24 | 2002-02-28 | Lytone Enterprise, Inc. | Delayed release compositions and combinations |
US6955648B2 (en) * | 2000-09-29 | 2005-10-18 | New Health Sciences, Inc. | Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound |
WO2002028275A2 (en) | 2000-09-29 | 2002-04-11 | New Health Sciences, Inc. | Systems and methods for investigating blood flow |
US7104958B2 (en) * | 2001-10-01 | 2006-09-12 | New Health Sciences, Inc. | Systems and methods for investigating intracranial pressure |
WO2002062300A2 (en) * | 2001-02-07 | 2002-08-15 | The Mclean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
JP2004525109A (ja) | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | 安定化された甲状腺ホルモン医薬組成物、及びその製法 |
US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
MXPA03007338A (es) * | 2001-02-15 | 2005-06-06 | King Pharmaceuticals Inc | Fabricacion de tabletas de hormona tiroidea que tienen cantidades consistentes de la porcion activa. |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
JP4425628B2 (ja) * | 2001-07-23 | 2010-03-03 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法 |
SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
US7708712B2 (en) * | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
AU2002341699A1 (en) * | 2001-09-18 | 2003-04-01 | The Johns Hopkins University | Specific depletion of cd4+t cells |
US20040044226A1 (en) * | 2001-10-15 | 2004-03-04 | Dininno Frank P. | Estrogen receptor modulators |
US20030165564A1 (en) * | 2001-10-29 | 2003-09-04 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
EP1451577A4 (en) * | 2001-11-05 | 2006-03-15 | Brigham & Womens Hospital | SOLUBLE CD40L (CD154) AS A PROGNOSEMARKER FOR ATHEROSCLEROSIS DISEASES |
ES2289153T7 (es) * | 2001-11-08 | 2009-06-18 | Atrium Medical Corporation | Dispositivo intraluminal con un revestimiento que contiene un agente terapeutico. |
US6706756B1 (en) | 2001-11-16 | 2004-03-16 | University Of South Florida | Vasodilating compound and method of use |
US7030159B2 (en) | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
US7582785B2 (en) | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
PL372246A1 (en) * | 2002-05-28 | 2005-07-11 | 3-Dimensional Pharmaceuticals, Inc. | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
US7375131B2 (en) * | 2002-06-06 | 2008-05-20 | Smithklinebeecham Corp. | NF-κB inhibitors |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
EP3584235A3 (en) | 2002-08-12 | 2020-04-22 | Brigham and Women's Hospital | Resolvins: biotemplates for novel therapeutic interventions |
CA2499501A1 (en) | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
SE0300092D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
WO2004078143A2 (en) * | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
JP4660471B2 (ja) * | 2003-03-14 | 2011-03-30 | セルテック アール アンド ディー, インコーポレイテッド | TGFβ結合タンパク質のリガンドおよびその使用 |
CA2529623A1 (en) * | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
JP2007517550A (ja) * | 2004-01-02 | 2007-07-05 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | 高比重リポ蛋白をコーティングした医療デバイス |
EP1755537A4 (en) * | 2004-04-14 | 2009-12-09 | Univ Boston | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA |
US20050267197A1 (en) * | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses |
US20050267091A1 (en) * | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses |
FR2871061B1 (fr) * | 2004-06-04 | 2007-08-10 | Coletica Sa | Principe actif capable d'induire la transformation du tgbf- latent inactif en tgfb actif |
US20060039890A1 (en) * | 2004-08-20 | 2006-02-23 | Renshaw Perry F | Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US20060088596A1 (en) * | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
AU2005314197A1 (en) * | 2004-12-06 | 2006-06-15 | Reliant Pharmaceuticals, Inc. | Stable compositions of fenofibrate with fatty acid esters |
MX2007006707A (es) * | 2004-12-06 | 2008-01-16 | Reliant Pharmaceuticals Inc | Acidos grasos omega-3 y agente dislipidemico para terapia lipidica. |
CN101208083A (zh) * | 2005-03-08 | 2008-06-25 | 瑞莱恩特医药品有限公司 | 利用他汀和Omega-3脂肪酸治疗及其组合产品 |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
AP2007004245A0 (en) | 2005-05-13 | 2007-12-31 | Virochem Pharma Inc | Compounds and methods for the treatment or prevention of flavivirus infections |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
WO2007041440A2 (en) | 2005-10-03 | 2007-04-12 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers |
AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
WO2007048471A1 (en) * | 2005-10-25 | 2007-05-03 | Unilever N.V. | Food composition |
JP2009515991A (ja) | 2005-11-18 | 2009-04-16 | トラスティーズ オブ ボストン ユニバーシティ | レゾルビンを使用する骨喪失の処置および防止 |
EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
EP2423226A3 (en) * | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
NZ576780A (en) | 2006-11-15 | 2011-12-22 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
US20080194527A1 (en) * | 2007-02-14 | 2008-08-14 | Tcp Innovations Ltd | Compositions and combinations 2 |
GB0702871D0 (en) * | 2007-02-14 | 2007-03-28 | Tcp Innovations Ltd | Improved compositions and combinations 1 |
CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
CN101896201A (zh) * | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
MX2010005704A (es) * | 2007-12-18 | 2010-08-17 | Glenmark Pharmaceuticals Sa | Derivados de cromano como modulares del trpv3. |
US20090163452A1 (en) * | 2007-12-20 | 2009-06-25 | Schwartz Janice B | Compositions and methods for lowering serum cholesterol |
NZ595780A (en) * | 2008-06-17 | 2013-07-26 | Glenmark Pharmaceuticals Sa | Chromane derivatives as trpv3 modulators |
CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
US20110196383A1 (en) * | 2009-05-05 | 2011-08-11 | Atherolysis Medical, Inc | Atherosclerotic Plaque Dissolution Composition |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US20120252862A1 (en) * | 2009-09-28 | 2012-10-04 | Yeditepe Universites | Dissolvable Film Strip Comprising Natural Components |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US20110136858A1 (en) * | 2009-12-04 | 2011-06-09 | Grainger David J | Preferred Combination Therapy |
GB2475907A (en) | 2009-12-04 | 2011-06-08 | Tcp Innovations Ltd | Composition comprising a mixture of clopidogrel and droloxifene |
US20110184006A1 (en) * | 2010-01-28 | 2011-07-28 | National Research Council Of Sri Lanka | Method and composition for thermally stabilizing vitamin c within nano layers of montmorillonite clay |
US8465939B2 (en) * | 2010-03-02 | 2013-06-18 | Nox Technologies, Inc. | Aging-related circulating particle-associated lipoprotein B oxidase (apoBNOX) and inhibitors thereof |
US20110269849A1 (en) * | 2010-05-03 | 2011-11-03 | Yuan Yao | Emulsions and Methods for the Preparation Thereof, and Methods for Improving Oxidative Stability of Lipids |
ME02819B (me) | 2010-05-14 | 2018-01-20 | Amgen Inc | Formulacije sa visokom koncentracijom antitijela |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
EA029956B1 (ru) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Кристаллы антител против склеростина и составы на их основе |
WO2013019954A1 (en) | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
KR20190120401A (ko) | 2011-12-28 | 2019-10-23 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
JP7384817B2 (ja) * | 2017-12-14 | 2023-11-21 | キャロリー ヘルス サイエンス エルエルシー | アテローム性動脈硬化病変を硫酸多糖で安定化及び改善する方法 |
SG11202008206TA (en) | 2018-03-30 | 2020-09-29 | Amgen Inc | C-terminal antibody variants |
WO2023177676A1 (en) * | 2022-03-14 | 2023-09-21 | University Of South Florida | Genistein for asthma treatment |
Family Cites Families (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US528040A (en) * | 1894-10-23 | Telephone circuit and signal | ||
GB1015787A (en) | 1962-08-03 | 1966-01-05 | Giuseppe Carlo Sigurta | Tris-(p-methoxyphenyl)ethylene derivatives |
US3445473A (en) * | 1965-04-10 | 1969-05-20 | Hoechst Ag | 3-anilino-thiophene-4-carboxylic acids,esters,and amides |
US3634517A (en) * | 1968-08-19 | 1972-01-11 | Richardson Merrell Inc | Triarylalkenones |
US5521171A (en) | 1975-03-31 | 1996-05-28 | Sorenson; John R. J. | Anti-inflammatory and anti-ulcer compounds and process |
US4221785A (en) | 1978-05-30 | 1980-09-09 | Sorenson John R J | Anti-inflammatory and anti-ulcer compounds and process |
US5082834A (en) | 1978-05-30 | 1992-01-21 | Sorensen John R J | Anti-inflammatory and anti-ulcer compounds and process |
US6306846B1 (en) * | 1972-05-31 | 2001-10-23 | John R. J. Sorenson | Anti-inflammatory and anti-ulcer compounds and process |
IT1070993B (it) * | 1973-12-24 | 1985-04-02 | Bioindustria Spa | Derivati del tiofene ad attivita antimicotica e tricomonicida |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4323707A (en) * | 1975-10-28 | 1982-04-06 | Eli Lilly And Company | Antifertility compounds |
US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4317915A (en) * | 1976-08-23 | 1982-03-02 | Hoffmann-La Roche Inc. | Novel thiophene derivatives |
US4428963A (en) * | 1976-08-23 | 1984-01-31 | Hoffmann-La Roche Inc. | Novel thiophene derivatives |
CH628628A5 (en) * | 1976-08-23 | 1982-03-15 | Hoffmann La Roche | Process for the preparation of cyclic compounds |
JPS6012381B2 (ja) | 1976-10-06 | 1985-04-01 | 久光製薬株式会社 | 温熱湿布剤 |
DE2861560D1 (en) | 1977-11-28 | 1982-03-04 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
US4440754A (en) | 1978-05-30 | 1984-04-03 | Sorenson John R J | Anti-inflammatory and anti-ulcer compounds and process |
US4239778A (en) * | 1978-09-12 | 1980-12-16 | The University Of Illinois Foundation | Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation |
US4219656A (en) * | 1978-10-24 | 1980-08-26 | American Cyanamid Company | 3,4-Disubstituted thiophenes |
US4315028A (en) | 1978-12-22 | 1982-02-09 | Scheinberg Israel H | Method of treatment of rheumatoid arthritis |
DE3060722D1 (en) * | 1979-05-15 | 1982-09-30 | Ici Plc | 1-hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them |
US4382143A (en) * | 1979-07-23 | 1983-05-03 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs |
AU532174B2 (en) | 1979-08-15 | 1983-09-22 | Stephen James Beveridge | Copper chelate compounds |
US4487780A (en) | 1979-09-18 | 1984-12-11 | Scheinberg Israel H | Method of treatment of rheumatoid arthritis |
US4879315A (en) * | 1982-03-30 | 1989-11-07 | The Board Of Regents For The University Of Oklahoma | Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents |
US5098903A (en) * | 1980-03-07 | 1992-03-24 | Board Of Regents Of The University Of Oklahoma | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
US5658927A (en) * | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
US4282246A (en) * | 1980-03-07 | 1981-08-04 | Pfizer Inc. | Antidiabetic furancarboxylic and thiphenecarboxylic acids |
US5658951A (en) * | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
EP0038868B1 (de) | 1980-04-29 | 1983-09-28 | Blendax-Werke R. Schneider GmbH & Co. | Zahnpasta |
ATE4775T1 (de) | 1980-04-29 | 1983-10-15 | Blendax-Werke R. Schneider Gmbh & Co. | Zahnpasta. |
US4442119A (en) * | 1980-07-07 | 1984-04-10 | The Board Of Regents For The University Of Oklahoma | Cyclopropyl analogs as estrogenic and anti-fertility agents |
DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4670428A (en) | 1982-02-01 | 1987-06-02 | International Copper Research Association, Inc. | Method for treating convulsions and epilepsy with organic copper compounds |
US5015666A (en) * | 1982-03-30 | 1991-05-14 | Board of Reagents of the University of Oklahoma | Triarylcyclopropanes as antiestrogens and antitumor agents |
US4657928A (en) | 1982-05-27 | 1987-04-14 | International Copper Research Association, Inc. | Organic copper complexes as radioprotectants |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
US4952607A (en) * | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
JPS5942375A (ja) * | 1982-09-03 | 1984-03-08 | Mitsubishi Petrochem Co Ltd | 4−ヒドロキシ−2−チオフエン酢酸誘導体 |
US5656587A (en) | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
US5705477A (en) | 1982-09-24 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use |
US4491574A (en) | 1983-03-02 | 1985-01-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Reduction of high dose aspirin toxicity by dietary vitamin A |
US4629694A (en) | 1983-07-12 | 1986-12-16 | Cornell Research Foundation, Inc. | Detecting and distinguishing between plasminogen activators |
IT1198654B (it) * | 1983-07-26 | 1988-12-21 | Edoardo Furia | Macchina automatica per la fabbricazione estemporanea e la distribuzione di ghiaccioli sorbetti ed altro |
EP0170063B1 (en) | 1984-07-31 | 1988-08-24 | Mitsubishi Petrochemical Co., Ltd. | Copper-type conductive coating composition |
US4758554A (en) | 1984-08-14 | 1988-07-19 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4758555A (en) * | 1984-08-14 | 1988-07-19 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4757059A (en) | 1984-08-14 | 1988-07-12 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
IT1196390B (it) * | 1984-12-28 | 1988-11-16 | Consiglio Nazionale Ricerche | Uso di derivati del tiofene nel trattamento dei tumori,composizioni farmaceutiche che li contengono e composti atti allo scopo |
US4760051A (en) | 1985-01-24 | 1988-07-26 | Pickart Loren R | Use of GHL-Cu as a wound-healing and anti-inflammatory agent |
US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US5262319A (en) | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
US5470876A (en) | 1985-07-18 | 1995-11-28 | Proctor; Peter H. | Topical sod for treating hair loss |
DE3532860C1 (de) | 1985-09-14 | 1987-03-12 | Blendax Werke Schneider Co | Mittel zur oralen Hygiene |
US4853377A (en) | 1985-10-15 | 1989-08-01 | Pollack Robert L | Method and composition for increasing production of serotonin |
US5120535A (en) | 1986-11-26 | 1992-06-09 | Oncogen | Oncostatin M and novel compositions having anti-neoplastic activity |
US4999347A (en) | 1986-08-28 | 1991-03-12 | Sorenson John R J | Analgesic method |
US5216021A (en) | 1986-08-28 | 1993-06-01 | Sorenson John R J | Analgesic method |
EP0260066B1 (en) * | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifen derivatives |
HU199281B (en) | 1986-10-17 | 1990-02-28 | Biogal Gyogyszergyar | Synergetic unsenziting face- and body-cosmetics |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
DE3781546D1 (de) * | 1987-04-21 | 1992-10-08 | Heumann Pharma Gmbh & Co | Stabile loesungsmitteladdukte von z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en. |
US5114719A (en) * | 1987-04-29 | 1992-05-19 | Sabel Bernhard A | Extended drug delivery of small, water-soluble molecules |
SE8702254D0 (sv) | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | Novel heparin derivatives |
US5221620A (en) | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
DE3737340A1 (de) | 1987-11-04 | 1989-05-24 | Bayer Ag | Neue fluormethoxyphenyl-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5705609A (en) | 1988-06-28 | 1998-01-06 | La Jolla Cancer Research Foundation | Decorin fragments inhibiting cell regulatory factors |
US4956188A (en) | 1988-10-20 | 1990-09-11 | Zinpro Corporation | Copper complexes with alpha hydroxy organic acids and their use as nutritional supplements |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5393785A (en) * | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
CA2002011A1 (en) | 1988-11-14 | 1990-05-14 | Anthony F. Purchio | Normal human growth regulatory receptor for tgf-beta |
CA2005120A1 (en) | 1988-12-15 | 1990-06-15 | Anthony F. Purchio | Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta |
US5304541A (en) | 1988-12-15 | 1994-04-19 | Bristol-Myers Squibb Company | Methods using novel chimeric transforming growth factor-β1/β2 |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US4900561A (en) | 1989-01-03 | 1990-02-13 | Zinpro Corporation | Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements |
US4948594A (en) | 1989-01-03 | 1990-08-14 | Zinpro Corporation | Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements |
US5356630A (en) | 1989-02-22 | 1994-10-18 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US5118791A (en) | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5100885A (en) | 1989-08-01 | 1992-03-31 | Johnson Matthey, Inc. | Copper radiosensitizers |
US4990538A (en) * | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
US5145838A (en) | 1989-08-30 | 1992-09-08 | Procyte Corporation | Methods and compositions for healing ulcers |
US5023237A (en) | 1989-08-30 | 1991-06-11 | Procyte Corporation | Methods and compositions for healing ulcers |
US5158934A (en) * | 1989-09-01 | 1992-10-27 | Genentech, Inc. | Method of inducing bone growth using TGF-β |
IL95500A (en) | 1989-09-11 | 1997-03-18 | Matrix Pharma | ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE |
US5126348A (en) | 1989-09-26 | 1992-06-30 | The University Of Colorado Foundation, Inc. | Bioavailability enhancers |
US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
AU634871B2 (en) | 1990-03-20 | 1993-03-04 | Banyu Pharmaceutical Co., Ltd. | Substituted amine derivatives having anti-hyperlipemia activity |
US5108989A (en) | 1990-04-04 | 1992-04-28 | Genentech, Inc. | Method of predisposing mammals to accelerated tissue repair |
US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
US5401730A (en) * | 1990-07-06 | 1995-03-28 | The Hope Heart Institute | Method for reducing platelet aggregation |
US5189212A (en) * | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
US5219548A (en) * | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
US5824647A (en) | 1990-12-12 | 1998-10-20 | Postlethwaite; Arnold E. | Chemotactic wound healing peptides |
WO1992011895A1 (en) * | 1990-12-28 | 1992-07-23 | Boston Scientific Corporation | Balloon drug delivery system |
US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
IT1247527B (it) * | 1991-04-24 | 1994-12-17 | Medea Res Srl | Agente antiarteriosclerotico, sua preparazione ed uso |
US5229495A (en) | 1991-06-18 | 1993-07-20 | Ludwig Institute For Cancer Research | Substantially pure receptor like TGF-β 1 binding molecules and uses thereof |
US5216126A (en) | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
JP3446214B2 (ja) | 1991-06-21 | 2003-09-16 | ライオン株式会社 | 液状透明口腔用組成物 |
US5126021A (en) * | 1991-07-17 | 1992-06-30 | Applied Biosystems Inc. | Low-viscosity polymer solution for capillary electrophoresis |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
AU2738392A (en) | 1991-11-11 | 1993-05-13 | Ciba-Geigy Ag | Novel hybrid transforming growth factors |
EP0622076B1 (en) * | 1992-01-17 | 1997-04-02 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for restenosis after percutaneous coronary arterioplasty |
US5280109A (en) | 1992-01-27 | 1994-01-18 | Ludwig Institute For Cancer Research | Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2 |
US5444164A (en) | 1992-02-05 | 1995-08-22 | Bristol-Myers Squibb Company | TGF-β induced gene |
WO1993019177A1 (en) | 1992-03-18 | 1993-09-30 | The General Hospital Corporation | FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY |
GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
DE69321596T2 (de) * | 1992-07-30 | 1999-04-22 | Cal International Ltd | Ester und kombinationen von einem organischen nitrat und einem salicyclat |
US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
JPH08504763A (ja) | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 治療薬としてのTGF−βレセプターフラグメントの使用 |
GB2273873A (en) | 1992-12-23 | 1994-07-06 | Univ Sheffield | Treatment of psoriasis |
US5420243A (en) | 1993-01-26 | 1995-05-30 | Celtrix Pharmaceuticals, Inc. | Biologically active TGF-β2 peptides |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5451603A (en) * | 1993-03-11 | 1995-09-19 | Zymogenetics, Inc. | 3,4-diarylchromans for treatment of dermatitis |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
ATE406909T1 (de) | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
US5409955A (en) | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US5445941A (en) * | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
IL109990A (en) * | 1993-06-21 | 1999-06-20 | Lilly Co Eli | Materials and methods for screening anti-osteoporosis agents |
DE4320898A1 (de) | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten |
DE4320896A1 (de) | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
TW303299B (US06734208-20040511-C00003.png) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
DK0711158T4 (da) | 1993-07-29 | 2008-11-03 | Us Gov Health & Human Serv | Metode til behandling af atherosclerose eller restenose ved anvendelse af mikrotubulus-stabiliserende middel |
US5461065A (en) * | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
US5441964A (en) * | 1993-10-15 | 1995-08-15 | Eli Lilly And Company | Methods for inhibiting bone loss using substituted benzothiophene |
US5482950A (en) * | 1993-10-15 | 1996-01-09 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5418252A (en) * | 1993-10-15 | 1995-05-23 | Eli Lilly And Company | Method for inhibiting cartilage degradation |
US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
US5480904A (en) * | 1993-10-28 | 1996-01-02 | Eli Lilly And Company | Methods for inhibiting uterine fibrosis |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
US5462950A (en) * | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of treating menstrual symptoms and compositions therefore |
US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
US5574047A (en) * | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
US5446053A (en) * | 1993-12-21 | 1995-08-29 | Eli Lilly And Company | Methods of inhibiting dysfunctional uterine bleeding |
US5451590A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly & Co. | Methods of inhibiting sexual precocity |
US5439923A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method of inhibiting seborrhea and acne |
US5389670A (en) * | 1993-12-21 | 1995-02-14 | Eli Lilly Company | Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder |
US5439931A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
US5461064A (en) * | 1993-12-21 | 1995-10-24 | Eli Lilly And Company | Methods of inhibiting atrophy of the skin and vagina |
US5462949A (en) * | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of inhibiting fertility in women |
US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5534526A (en) * | 1993-12-21 | 1996-07-09 | Eli Lilly And Company | Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome |
US5521198A (en) * | 1993-12-21 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting autoimmune diseases |
US5451589A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly And Company | Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism |
US5441966A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5708009A (en) * | 1993-12-21 | 1998-01-13 | Eli Lilly And Company | Methods of inhibiting myeloperoxidase activity |
US5852047A (en) * | 1994-01-28 | 1998-12-22 | Cal International Limited | Pharmaceutical product comprising a salicylate of an esterifiable ace-inhibitor |
US5591753A (en) * | 1994-01-28 | 1997-01-07 | Eli Lilly And Company | Combination treatment for osteoporosis |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
IL112746A (en) * | 1994-03-02 | 1999-12-31 | Lilly Co Eli | Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride |
US5451414A (en) | 1994-03-15 | 1995-09-19 | Heritage Environmental Services, Inc. | Micronutrient supplement |
CA2145614A1 (en) | 1994-03-31 | 1995-10-01 | Jeffrey A. Dodge | Intermediates and processes for preparing benzothiophene compounds |
SE9401174D0 (sv) * | 1994-04-07 | 1994-04-07 | Astra Ab | New combination |
US5455275A (en) * | 1994-05-11 | 1995-10-03 | Eli Lilly And Company | Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives |
JPH07316192A (ja) | 1994-05-27 | 1995-12-05 | Hoechst Japan Ltd | L−リシル−グリシル−l−ヒスチジンおよびこれを含有する創傷治療剤 |
US5656450A (en) | 1994-05-27 | 1997-08-12 | Board Of Regents, The University Of Texas System | Activation of latent transforming growth factor β by matrix vesicles |
US5466810A (en) * | 1994-06-10 | 1995-11-14 | Eli Lilly And Company | 2-amino-3-aroyl-benzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)-benzoyl]benzo[β]thiophenes |
US5441986A (en) * | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
EP0800530A4 (en) * | 1994-07-20 | 1998-12-02 | Celtrix Pharma | IGF / IGFBP COMPLEX FOR PROMOTING BONE TRAINING AND REGULATING BONE REMODELING |
US5496828A (en) * | 1994-08-22 | 1996-03-05 | Eli Lilly And Company | Methods of inhibiting ulcerative mucositis |
US5434166A (en) * | 1994-08-22 | 1995-07-18 | Eli Lilly And Company | Methods of inhibiting demyelinating and desmyelinating diseases |
US5491159A (en) * | 1994-08-30 | 1996-02-13 | American Home Products Corporation | 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents |
US5731436A (en) | 1994-08-31 | 1998-03-24 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5660873A (en) | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US7501441B1 (en) * | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
US5489587A (en) * | 1995-01-20 | 1996-02-06 | Eli Lilly And Company | Benzofurans used to inhibit bone loss |
US5571808A (en) * | 1995-01-31 | 1996-11-05 | Eli Lilly And Company | Method for treating smoking-related bone loss |
US5484808A (en) * | 1995-02-09 | 1996-01-16 | Eli Lilly And Company | Methods of inhibiting cell-cell adhesion |
US5563054A (en) * | 1995-03-31 | 1996-10-08 | Eli Lilly And Company | Process for preparation of benzo[B]thiophene glucuronides |
IL120269A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease |
US5912006A (en) | 1996-08-28 | 1999-06-15 | Eboc, Inc. | Compositions and methods for alleviating discomforting menstrual pain |
US5865766A (en) * | 1997-01-10 | 1999-02-02 | Emory University | Multichannel, multipurpose sample collection and drug delivery system for laboratory animals |
US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6765012B2 (en) * | 2001-09-27 | 2004-07-20 | Allergan, Inc. | 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
US7005444B2 (en) * | 2001-09-27 | 2006-02-28 | Allergan, Inc. | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
-
1998
- 1998-04-09 US US09/057,323 patent/US6117911A/en not_active Expired - Fee Related
- 1998-04-09 WO PCT/US1998/007063 patent/WO1998046588A2/en active Application Filing
- 1998-04-09 AU AU69598/98A patent/AU6959898A/en not_active Abandoned
-
2000
- 2000-05-05 US US09/567,558 patent/US6410587B1/en not_active Expired - Fee Related
-
2002
- 2002-06-13 US US10/170,971 patent/US6734208B2/en not_active Expired - Fee Related
-
2004
- 2004-04-19 US US10/827,602 patent/US7084171B2/en not_active Expired - Fee Related
-
2005
- 2005-11-09 US US11/270,185 patent/US7511070B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20060084696A1 (en) | 2006-04-20 |
US7511070B2 (en) | 2009-03-31 |
WO1998046588A3 (en) | 1999-01-07 |
US6734208B2 (en) | 2004-05-11 |
US6117911A (en) | 2000-09-12 |
US6410587B1 (en) | 2002-06-25 |
US20050020667A1 (en) | 2005-01-27 |
US20030064970A1 (en) | 2003-04-03 |
WO1998046588A2 (en) | 1998-10-22 |
US7084171B2 (en) | 2006-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6959898A (en) | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies | |
AU8140898A (en) | Inhibitors of beta-lactamases and uses therefor | |
IL132426A0 (en) | An amyloid binding compound and pharmaceutical compositions containing the same | |
AU2616695A (en) | Synergistic composition | |
AU2209599A (en) | Methods and systems for the inhibition of vascular hyperplasia | |
HUP0101031A3 (en) | Bicyclo[2.2.1]heptanes and related compounds | |
AU8693098A (en) | Compositions and methods for treating diabetes | |
AU3416695A (en) | Metal complex containing oligonucleoside cleavage compounds and therapies | |
AU5880498A (en) | New benzolactam derivatives and medicinal compositions containing the same | |
AU2939797A (en) | Aromatic esters of polyalkylphenoxyalkanols and fuel compositions containing the same | |
AU5733796A (en) | High-dose chromic tripicolinate for the treatment of type ii diabetes | |
AU1592299A (en) | Skin rash prevention composition | |
AU3124300A (en) | Inhibitors of beta-lactamases and uses therefor | |
AU1509999A (en) | Herbal drug composition for the prevention and treatment of dementia | |
AU671577B3 (en) | Compositions and methods for the control of smoking | |
AU1429697A (en) | Systems and methods for the transdermal administration of androgenic agents | |
AU2190400A (en) | Inhibitors of beta-lactamases and uses therefor | |
AU7685798A (en) | Compositions and methods for preventing adhesion | |
AU1556497A (en) | Agents for the treatment and prevention of aids | |
AU3899893A (en) | Compositions for the treatment of acute or chronic inflammation | |
AU6303898A (en) | Component of bromelain | |
AU1277799A (en) | Polycyclic alpha-amino-$m(e)-caprolactams and related compounds | |
AU1454599A (en) | Compounds inhibiting cd4-gp120 interaction and uses thereof | |
AU6094598A (en) | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures | |
AU4563093A (en) | Echographic contrast agent composition |